Manufacturing capacity shifting to COVID-19 vaccines is delaying Novavax, Inc.’s regulatory filings for its flu vaccine, CEO Stanley Erck said.
Even as the firm builds production capacity for its investigational coronavirus vaccine through a deal with Serum Institute of...







